ANAPTYSBIO INC (ANAB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ANAB • US0327241065

48.38 USD
-2.83 (-5.53%)
At close: Feb 4, 2026
47.7 USD
-0.68 (-1.41%)
After Hours: 2/4/2026, 8:03:33 PM
Fundamental Rating

3

Overall ANAB gets a fundamental rating of 3 out of 10. We evaluated ANAB against 524 industry peers in the Biotechnology industry. ANAB has a bad profitability rating. Also its financial health evaluation is rather negative. ANAB is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ANAB has reported negative net income.
  • ANAB had a negative operating cash flow in the past year.
  • ANAB had negative earnings in each of the past 5 years.
  • In the past 5 years ANAB always reported negative operating cash flow.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • ANAB has a Return On Assets of -23.97%. This is in the better half of the industry: ANAB outperforms 72.71% of its industry peers.
Industry RankSector Rank
ROA -23.97%
ROE N/A
ROIC N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • ANAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ANAB has been increased compared to 1 year ago.
  • Compared to 5 years ago, ANAB has more shares outstanding
  • Compared to 1 year ago, ANAB has a worse debt to assets ratio.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • ANAB has an Altman-Z score of 0.05. This is a bad value and indicates that ANAB is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of 0.05, ANAB is doing good in the industry, outperforming 61.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.05
ROIC/WACCN/A
WACC9.69%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 8.68 indicates that ANAB has no problem at all paying its short term obligations.
  • ANAB has a Current ratio of 8.68. This is in the better half of the industry: ANAB outperforms 77.10% of its industry peers.
  • A Quick Ratio of 8.68 indicates that ANAB has no problem at all paying its short term obligations.
  • The Quick ratio of ANAB (8.68) is better than 77.10% of its industry peers.
Industry RankSector Rank
Current Ratio 8.68
Quick Ratio 8.68
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • ANAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.62%, which is quite impressive.
  • ANAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 196.42%.
  • The Revenue has been growing by 62.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)53.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%145.61%
Revenue 1Y (TTM)196.42%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%154.26%

3.2 Future

  • ANAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
  • The Revenue is expected to grow by 42.41% on average over the next years. This is a very strong growth
EPS Next Y76.09%
EPS Next 2Y5.14%
EPS Next 3Y-5.13%
EPS Next 5Y10.53%
Revenue Next Year280.69%
Revenue Next 2Y50.09%
Revenue Next 3Y47.7%
Revenue Next 5Y42.41%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ANAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ANAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ANAB's earnings are expected to decrease with -5.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.14%
EPS Next 3Y-5.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ANAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANAPTYSBIO INC

NASDAQ:ANAB (2/4/2026, 8:03:33 PM)

After market: 47.7 -0.68 (-1.41%)

48.38

-2.83 (-5.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-25
Inst Owners114.62%
Inst Owner Change-2.63%
Ins Owners2.52%
Ins Owner Change0.93%
Market Cap1.34B
Revenue(TTM)169.47M
Net Income(TTM)-84.63M
Analysts84.21
Price Target63.92 (32.12%)
Short Float %21.35%
Short Ratio11.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)75.1%
Min EPS beat(2)14.78%
Max EPS beat(2)135.42%
EPS beat(4)3
Avg EPS beat(4)51.62%
Min EPS beat(4)-0.12%
Max EPS beat(4)135.42%
EPS beat(8)5
Avg EPS beat(8)21.13%
EPS beat(12)8
Avg EPS beat(12)13.53%
EPS beat(16)8
Avg EPS beat(16)-5.01%
Revenue beat(2)2
Avg Revenue beat(2)231.08%
Min Revenue beat(2)88.94%
Max Revenue beat(2)373.21%
Revenue beat(4)4
Avg Revenue beat(4)246.14%
Min Revenue beat(4)78.26%
Max Revenue beat(4)444.15%
Revenue beat(8)7
Avg Revenue beat(8)203.82%
Revenue beat(12)9
Avg Revenue beat(12)133.49%
Revenue beat(16)9
Avg Revenue beat(16)78.7%
PT rev (1m)9.94%
PT rev (3m)9.77%
EPS NQ rev (1m)-2.37%
EPS NQ rev (3m)213.65%
EPS NY rev (1m)1.61%
EPS NY rev (3m)70.92%
Revenue NQ rev (1m)-0.81%
Revenue NQ rev (3m)135.19%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)89.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.91
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.82
EYN/A
EPS(NY)-4.66
Fwd EYN/A
FCF(TTM)-5.25
FCFYN/A
OCF(TTM)-5.24
OCFYN/A
SpS6.12
BVpS-1.06
TBVpS-1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.91%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.68
Quick Ratio 8.68
Altman-Z 0.05
F-Score4
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)78.6%
Cap/Depr(5y)111.71%
Cap/Sales(3y)2.86%
Cap/Sales(5y)2.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%145.61%
EPS Next Y76.09%
EPS Next 2Y5.14%
EPS Next 3Y-5.13%
EPS Next 5Y10.53%
Revenue 1Y (TTM)196.42%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%154.26%
Revenue Next Year280.69%
Revenue Next 2Y50.09%
Revenue Next 3Y47.7%
Revenue Next 5Y42.41%
EBIT growth 1Y79.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.74%
EBIT Next 3Y28.67%
EBIT Next 5YN/A
FCF growth 1Y-48.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.26%
OCF growth 3YN/A
OCF growth 5YN/A

ANAPTYSBIO INC / ANAB FAQ

What is the fundamental rating for ANAB stock?

ChartMill assigns a fundamental rating of 3 / 10 to ANAB.


Can you provide the valuation status for ANAPTYSBIO INC?

ChartMill assigns a valuation rating of 0 / 10 to ANAPTYSBIO INC (ANAB). This can be considered as Overvalued.


What is the profitability of ANAB stock?

ANAPTYSBIO INC (ANAB) has a profitability rating of 1 / 10.


How financially healthy is ANAPTYSBIO INC?

The financial health rating of ANAPTYSBIO INC (ANAB) is 3 / 10.